deltatrials
Completed PHASE3 NCT00073840

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Sponsor: Sumitomo Pharma America, Inc.

Conditions Asthma
Interventions levalbuterol
Updated 8 times since 2017 Last updated: Feb 21, 2012 Started: Dec 31, 2002 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Sep 2023 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States, Barnesville, United States, Bay Shore, United States, Burke, United States, Charlotte, United States, Chicago, United States, Cincinnati, United States, Conyers, United States, Corona, United States, Cortland, United States and 42 more location s